Determination of HER2 by fluorescence in situ hybridization (FISH) in breast cancer. Experience of the reference laboratory of Lisbon;Determinação da amplificação do HER2 por hibridação in situ de fluorescência (FISH)
Breast cancer; Fluorescence in situ hybridization (FISH); HER2
Indexed keywords
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
TRASTUZUMAB;
ARTICLE;
BREAST CANCER;
CANCER INVASION;
CONTROLLED STUDY;
FLUORESCENCE IN SITU HYBRIDIZATION;
GENE AMPLIFICATION;
HOSPITAL;
HUMAN;
LABORATORY TEST;
MAJOR CLINICAL STUDY;
PORTUGAL;
PROTEIN DETERMINATION;
BREAST TUMOR;
FEMALE;
GENETICS;
MALE;
PAGET NIPPLE DISEASE;
PATHOLOGY;
PROTO ONCOGENE;
BREAST NEOPLASMS;
BREAST NEOPLASMS, MALE;
CARCINOMA, DUCTAL, BREAST;
FEMALE;
GENES, ERBB-2;
HUMANS;
IN SITU HYBRIDIZATION, FLUORESCENCE;
MALE;
PORTUGAL;
Correlation between immunohistochemistry (Hercep Test) and fluorescence in situ hibrodization (FISH) for HER-2 in 426 breast carcinomas from 37 centres
DOWSETT M, BARTLETT J, ELLIS O et al: Correlation between immunohistochemistry (Hercep Test) and fluorescence in situ hibrodization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 2003;199:418-23
The HER2/neu Gene and protein in Breast Cancer 2003: Biomarker and target of Therapy
ROSS J, FLETCHER J, LINETTE G et al: The HER2/neu Gene and protein in Breast Cancer 2003: Biomarker and target of Therapy. The Oncologist 2003;4:307-25
Targeting HER2 as a therapeutic strategy for breast cancer: A paradigmatic shift of drug development in oncology
De LAURENTIIS M, CANCELLO G, ZINNO L et al: Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. Ann Oncol 2005;16:7-13
Predicting the HER2 status of breast cancer from basic histopatology data: An analysis of 1500 breast cancers as part of the HER 2000 International Study
BILOUS M, ADES C, ARMES J et al: Predicting the HER2 status of breast cancer from basic histopatology data: an analysis of 1500 breast cancers as part of the HER 2000 International Study. Breast 2003;12:92-8
HER - 2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization
HAMMOCK L, LEWIS M, PHILIPS C, COHEN CS: HER - 2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum Pathol 2003;34:1043-7
Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma
BOFIN AM, YTTERHUS B, MARTIN C, O'LEARY JJ, HAGMAR BM: Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma. Am J Clin Pathol 2004;122:110-9
Conference summary, Strategic Science Symposium - Her-27 neu testing of breast Cancer Patients in clinical pratice
ZARBO RJ, HAMMOND E: Conference summary, Strategic Science Symposium - Her-27 neu testing of breast Cancer Patients in clinical pratice. Arch Pathol Lab Med 2003;127:549-53
Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification
LAL P, SALAZAR PA, LADANYI M, CHEN B: Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification. J Mol Diagn 2003;5:155-9
Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing Hercep test and PathVysion FISH assay
VARSHNEY D, ZHOU GELLER, ALSABEH R: Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing Hercep test and PathVysion FISH assay. Am J Clin Pathol 2004;121:70-7
The role of Her2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast
LATTA EK, TJAN S, PARKES RK, O'MALLEY FP: The role of Her2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol 2002; 15: 1318-25
